Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A novel combination of ceria nanoparticles and mesenchymal stem cell nanovesicles modified both inflammation and autoimmunity in a mouse model of arthritis.
Using multi-omics analyses, researchers have identified two distinct immunological phenotypes of microscopic polyangiitis, which could inform prognosis and personalized treatment.
New findings support the use of targeted next-generation sequencing of NOD2 to reassess the diagnosis of juvenile idiopathic arthritis in patients with signs and symptoms suggestive of Blau syndrome.
Researchers have conducted a comprehensive single-cell analysis of synovial tissue in rheumatoid arthritis, providing insights into the heterogeneity of the disease and informing future treatment strategies.
New research shows that the amino acid l-arginine ameliorates arthritis and inhibits inflammatory bone loss by altering energy metabolism in osteoclasts.
Dual inhibition of glycolysis and glutaminolysis in fibroblast-like synoviocytes with a compound called c28MS shows promise in a mouse model of rheumatoid arthritis
Chromatin accessibility of an enhancer that regulates the expression of a disease-associated microRNA is affected in monocytes from patients with systemic lupus erythematosus, highlighting this enhancer as a potential therapeutic target.
New research shows that a recombinant antibody that binds type II collagen protects against the development of arthritis in mice by blocking neutrophil recruitment.
In an observational study, SARS-CoV-2 antibody therapy used as pre-exposure prophylaxis reduced the incidence of COVID-19 in individuals with rheumatic diseases.
New research shows that the FGF10–FGFR1 axis is highly activated in lining fibroblast-like synoviocytes during relapsing rheumatoid arthritis and is a potential therapeutic target.
New research shows that deficiency of the sulfation-related SLC26A2 affects osteocyte formation, and that targeting downstream mediators can ameliorate SLC26A2-deficient osteoporosis.
A monoclonal antibody targeting a peptide that replicates the proinflammatory properties of IL-17 has shown potent activity and an acceptable profile of adverse effects in pre-clinical studies.
New findings suggest that liposome-mediated delivery of a specific microRNA inhibitor can restore anti-inflammatory macrophage polarization and reduce joint inflammation in mice.
Although inflammatory arthritis induced by immune-checkpoint inhibitors clinically resembles that of rheumatoid arthritis or psoriatic arthritis, research shows that it differs in its associated T cell response.
Nanoparticles consisting of long DNA molecules in association with Ca2+ and PPi4− ions can modulate the pathological osteoporotic microenvironment and promote bone repair.
New research provides insights into the mechanisms underlying the renal protective effects of sodium glucose cotransporter 2 inhibitors in lupus nephritis.
An antibody that targets CD19 on B cells has shown greater inhibitory efficacy than that of anti-CD20 B cell depletion therapy in animal models of autoimmune diseases.
